AIIMS Study Reveals How Air Pollution Damages the Placenta and Changes Babies Before Birth

IMT News Desk
IMT News Desk
· 2 min read
AIIMS Delhi study reveals air pollution damages the placenta, restricts fetal growth up to 34%, increases low birth weight & preeclampsia risk

A groundbreaking study by researchers at All India Institute of Medical Sciences (AIIMS Delhi) has revealed that air pollution can damage the placenta, restrict fetal growth, and increase pregnancy complications, with effects that may extend well beyond birth.

The research, published in EMBO Molecular Medicine and funded by ICMR, examined how urban air pollution impacts pregnancy using laboratory experiments, animal models, and human pregnancy data. Scientists discovered that fine particulate matter, particularly PM2.5 and PM10, can cross the placental barrier and trigger inflammation and oxidative stress in the placenta.

Pollution particles interfere with the placenta’s critical ability to deliver oxygen and nutrients to the developing fetus by affecting blood vessel formation, nutrient transport, and healthy fetal growth. The study found that increased exposure to PM2.5 was linked to higher risks of low birth weight and preeclampsia, a serious pregnancy complication marked by high blood pressure.

Corresponding author Subhradip Karmakar, Professor of Biochemistry at AIIMS Delhi, explained that pollution particles breach the placental barrier and influence genes responsible for fetal growth. The team discovered toxic metals, including lead, cadmium, and antimony, accumulating in placental tissue, suggesting pollutants can reach the fetus and potentially influence growth and neurodevelopment.

One of the most significant findings involved IGFBP3, a gene crucial for fetal development that gets suppressed by pollution-induced inflammation. This suppression disrupts placental development and affects healthy fetal growth, potentially explaining why pollution exposure connects to poorer birth outcomes.

Animal study results showed striking outcomes: smaller litter sizes reduced by up to 25 percent, abnormal placental development, reduced birth weight by about 34 percent at term compared to controls, and slower growth in offspring. Researchers also observed behavioral and developmental changes in offspring after birth, including impaired motor coordination, heightened anxiety-like behavior, and altered stress responses.

The findings add to growing evidence that air pollution poses serious risks beyond respiratory and cardiovascular diseases, threatening maternal and child health. Researchers cautioned that the full scope of long-term impacts, including potential effects on motor development, cognitive function, cardiovascular health, cancer risk, and metabolic disorders, requires further transgenerational studies.

The team suggested immediate practical measures, such as pregnant women using masks in highly polluted areas and consuming antioxidant-rich diets as interim protections, while stressing that systemic pollution control remains essential. They recommended that pollution monitoring should be integrated into prenatal care.

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk